youtube_live
Q3 2026 earnings • released • EPS miss -19.01% • Revenue beat +65.26%
See resultschevron_right
AKTS:NASDAQ
Aktis Oncology Inc
$16.62
arrow_upward
+2.09%(+0.34) 1D
Nov 13, 4:00:01 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AKTS...
Open
$16.33
High
$16.73
Low
$15.76
Mkt. cap
893.27M
Avg. vol.
363.85K
Volume
244.55K
52-wk high
$34.19
52-wk low
$13.96
EPS
-$1.42
Shares outstanding
53.75M
No. of employees
79
Open
$16.33
High
$16.73
Low
$15.76
Mkt. cap
893.27M
Avg. vol.
363.85K
Volume
244.55K
52-wk high
$34.19
52-wk low
$13.96
EPS
-$1.42
Shares outstanding
53.75M
No. of employees
79
News stories
From web sources and news partners
The Motley Fool
·
1 hour ago
History Says Every S&P 500 Bear Market Has Ended the Same Way. Here's the Pattern.
TradingKey
·
10 hours ago
S&P 500 Forecast: Index Poised to Retest Record High in November After 500-Point Pullback, Biggest Daily Gain in Nearly Seven Months
TradingView
·
17 hours ago
EXCLUSIVE: S&P 500’s Sell-Off Tested Buffered ETFs: Expert Explains Why a 10% Buffer May Not Protect You as Expected
Traders Union
·
1 hour ago
Quinten Francois: Bitcoin and Ethereum underperform S&P 500 over five years
About Aktis Oncology Inc
CEO-
Employees79
Founded2020
HeadquartersBoston, Massachusetts, United States
SectorHealth Care
IndustryBiotechnology
Websiteaktisoncology.com
Analyst ratings
Based on 5 analysts giving stock ratings to AKTS in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for AKTS in the last 3 months.
Highest
Current $16.62
$40.00 (+140.67%)
Average
$35.80 (+115.40%)
Lowest
$33.00 (+98.56%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Alec Stranahan Bank of America Securities | Buy | Reiterated | $34.00 | +104.6% | 11/13/2026 |
Unknown Analyst Leerink Partners | Buy | Maintained | $33.00 | +98.6% | 11/13/2026 |
Jeff Jones Oppenheimer | Buy | Reiterated | $40.00 | +140.7% | 11/13/2026 |
David Nierengarten Wedbush | Buy | Maintained | $35.00 | +110.6% | 10/02/2026 |
David Lebowitz BMO Capital | Buy | Initiated | $37.00 | +122.6% | 08/18/2026 |
Unknown Analyst BMO Capital | Buy | Initiated | $37.00 | +122.6% | 08/18/2026 |
Jessica Fye J.P. Morgan | Buy | Reiterated | $33.00 | +98.6% | 08/14/2026 |
Alexandra Ramsey William Blair | Buy | Maintained | - | - | 08/14/2026 |
Christopher Raymond Raymond James | Buy | Initiated | $40.00 | +140.7% | 06/16/2026 |
Robert Burns H.C. Wainwright | Buy | Reiterated | $35.00 | +110.6% | 06/03/2026 |
Tyler Van Buren TD Cowen | Buy | Maintained | - | - | 05/11/2026 |
Sami Corwin William Blair | Buy | Initiated | $18.75 | +12.8% | 05/02/2026 |
Unknown Analyst William Blair | Buy | Initiated | $18.60 | +11.9% | 04/29/2026 |
Andy Hsieh William Blair | Buy | Initiated | $32.00 | +92.5% | 04/29/2026 |
Jonathan Chang Leerink Partners | Buy | Initiated | $31.00 | +86.5% | 02/03/2026 |
Last report
Nov 12, 2026
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
-$0.54 / -$0.45
-19.01%miss
arrow_downward
Revenue / Est. (USD)
3.90M / 2.36M
+65.26%beat
arrow_upward
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
Revenue | 1.87M | 3.23M | 3.38M | 3.90M |
Cost of goods sold | 16.49M | 20.04M | 25.28M | - |
Cost of revenue | 16.49M | 20.04M | 25.28M | - |
Research and development expenses | - | - | - | 32.12M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 2.75M | 5.90M | 7.00M | 6.53M |
Operating expense | 2.75M | 5.90M | 7.00M | 38.65M |
Total operating expenses | 19.24M | 25.93M | 32.28M | 38.65M |
Operating income | -17.38M | -22.71M | -28.90M | -34.75M |
Other non operating income | -11.00K | -3.00K | -10.00K | -14.00K |
EBT including unusual items | -15.14M | -18.32M | -24.14M | -29.94M |
EBT excluding unusual items | -15.14M | -18.32M | -24.14M | -29.94M |
Income tax expense | - | - | - | - |
Effective tax rate | - | - | - | - |
Other operating expenses | - | - | - | - |
Net income | -15.14M | -18.32M | -24.14M | -29.94M |
Net profit margin | -809.52% | -567.86% | -713.48% | -766.68% |
Earnings per share | - | -0.38 | -0.44 | -0.54 |
Interest and investment income | 2.25M | 4.38M | 4.76M | 4.82M |
Interest expense | - | - | - | - |
Net interest expenses | 2.25M | 4.38M | 4.76M | 4.82M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -16.68M | -22.05M | -28.02M | -33.80M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events